<DOC>
	<DOCNO>NCT00143793</DOCNO>
	<brief_summary>The objective study : - Evaluate sensitivity specificity NT-proBNP ( N-terminal prohormone brain natriuretic peptide ) new biomarker measurement diagnosis heart failure patient acute dyspnea and/or edema . - Determine exact biomarker cut-off point ( ) differentiation healthy person , patient heart failure patient dyspnea origin . - Evaluate treatment cost patient dyspnea special consideration NT-proBNP measurement .</brief_summary>
	<brief_title>NT-proBNP New Biomarkers Patients With Dyspnea and/or Peripheral Edema</brief_title>
	<detailed_description>Primary endpoint : - Sensitivity specificity biomarker measurement discrimination heart failure dyspnea origin . Secondary endpoint : - Determination Cut-off ( ) - Discrimination cardiac non-cardiac disease cause dyspnea peripheral edema - Determination treatment cost initial hospital stay - Evaluation resource saving implement NT-proBNP determination diagnosis . - Time diagnosis . - Hospitalization rate /Intensive care treatment rate day 1 28 - Duration initial hospital stay - 30-day re-hospitalization rate - 30 day mortality rate adverse event rate - 1 5 year mortality rate - 1 5 year rehospitalization rate</detailed_description>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<criteria>Age 1890 year Dyspnea or/and peripheral edema Informed consent Renal insufficiency creatinine &gt; 2.8mg/dl Anemia ( hemoglobin &lt; 8.0mg/dl ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>natruretic peptide</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>new biomarkers</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>acute myocardial infarction</keyword>
	<keyword>lung embolism</keyword>
</DOC>